NADAC acquisition cost data for ENALAPRIL 1 MG/ML ORAL SOLN. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 31722002015 | $1.89 | 2022-10-19 | Rx |
| 69238214107 | $1.89 | 2022-10-19 | Rx |
| 69452023746 | $1.89 | 2022-10-19 | Rx |
| 31722002015 | $1.89 | 2022-10-19 | Rx |
| 69238214107 | $1.89 | 2022-10-19 | Rx |
| 69452023746 | $1.89 | 2022-10-19 | Rx |
| 31722002015 | $1.89 | 2022-10-19 | Rx |
| 69238214107 | $1.89 | 2022-10-19 | Rx |
| 69452023746 | $1.89 | 2022-10-19 | Rx |
| 31722002015 | $1.89 | 2022-10-19 | Rx |
Generic: Enalapril Maleate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $90.5M | 2,847,574 | 620,665 | $0.3737 |
| 2020 | $71.2M | 2,627,066 | 577,005 | $0.3025 |
| 2021 | $57.1M | 2,381,544 | 541,783 | $0.2607 |
| 2022 | $50.9M | 2,198,231 | 506,781 | $0.2456 |
| 2023 | $53.7M | 2,055,500 | 482,684 | $0.2726 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $6.8M | 269,467 | 61,837 |
| Florida | $4.6M | 174,147 | 44,769 |
| California | $4.3M | 136,420 | 33,200 |
| Puerto Rico | $3.8M | 163,307 | 33,668 |
| Illinois | $3.5M | 136,892 | 34,363 |
| Texas | $3.4M | 132,557 | 35,047 |
| Pennsylvania | $2.5M | 90,060 | 20,926 |
| New Jersey | $2.5M | 93,415 | 23,285 |
| Michigan | $2.0M | 71,752 | 17,542 |
| North Carolina | $1.4M | 55,330 | 13,817 |
| Ohio | $1.4M | 55,770 | 13,359 |
| Wisconsin | $1.2M | 47,025 | 11,580 |
| Massachusetts | $978.4K | 31,047 | 7,420 |
| Alabama | $897.9K | 27,643 | 7,004 |
| Tennessee | $876.8K | 35,071 | 8,636 |
| Indiana | $803.3K | 33,507 | 8,520 |
| Missouri | $775.1K | 33,512 | 7,827 |
| Georgia | $741.7K | 30,707 | 7,591 |
| Virginia | $673.2K | 29,407 | 7,434 |
| Arizona | $638.0K | 23,933 | 6,552 |
| Washington | $616.3K | 22,830 | 5,701 |
| Louisiana | $613.9K | 29,766 | 6,751 |
| Oklahoma | $598.1K | 20,529 | 4,875 |
| Iowa | $576.2K | 25,104 | 5,958 |
| South Carolina | $563.0K | 22,403 | 5,850 |
| Kentucky | $510.9K | 22,440 | 5,064 |
| Minnesota | $488.6K | 15,064 | 3,598 |
| Connecticut | $462.1K | 18,009 | 4,542 |
| Maryland | $448.3K | 15,134 | 4,060 |
| Arkansas | $437.9K | 17,429 | 4,025 |
| West Virginia | $383.0K | 14,964 | 3,720 |
| Nebraska | $371.1K | 15,838 | 3,366 |
| Mississippi | $353.7K | 15,574 | 3,566 |
| Oregon | $349.3K | 12,403 | 3,245 |
| Kansas | $331.3K | 14,776 | 3,321 |
| Maine | $321.6K | 11,212 | 2,925 |
| Colorado | $278.6K | 10,747 | 2,861 |
| Nevada | $241.4K | 9,979 | 2,804 |
| New Hampshire | $222.9K | 8,022 | 2,072 |
| New Mexico | $216.2K | 7,526 | 2,012 |
| Rhode Island | $213.1K | 8,101 | 1,946 |
| North Dakota | $188.7K | 7,374 | 1,594 |
| Utah | $164.3K | 5,160 | 1,431 |
| Idaho | $150.8K | 5,515 | 1,388 |
| Vermont | $143.2K | 4,295 | 1,113 |
| Montana | $138.3K | 5,570 | 1,354 |
| South Dakota | $113.5K | 4,832 | 1,076 |
| Delaware | $101.3K | 4,108 | 1,084 |
| Wyoming | $64.0K | 2,424 | 608 |
| Hawaii | $59.4K | 2,212 | 637 |
| District of Columbia | $45.9K | 1,449 | 453 |
| Alaska | $38.5K | 1,276 | 333 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.